Presentation is loading. Please wait.

Presentation is loading. Please wait.

Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils  Henry Lin, MD, Kevin M Boesel, MD, Daniel T Griffith, MD, Calman Prussin,

Published byΑμάλθεια Δεσποτόπουλος Modified over 6 years ago

Similar presentations

Presentation on theme: "Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils  Henry Lin, MD, Kevin M Boesel, MD, Daniel T Griffith, MD, Calman Prussin,"— Presentation transcript:

1 Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils 
Henry Lin, MD, Kevin M Boesel, MD, Daniel T Griffith, MD, Calman Prussin, MD, Barbara Foster, MS, F.A Romero, MS, Robert Townley, MD, Thomas B Casale, MD  Journal of Allergy and Clinical Immunology  Volume 113, Issue 2, Pages (February 2004) DOI: /j.jaci

2 FIG 1 Effect of omalizumab on nasal volume reduction after ragweed challenge. a, Omalizumab group showed significant blunting of reduction in nasal volume after PD30 dose of ragweed (P < .001) at each visit compared with baseline. b, In the placebo group, there was no statistical significance between visits to baseline and to each other. Data are medians ± 95% CIs (∗∗∗P < .001). Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

3 FIG 1 Effect of omalizumab on nasal volume reduction after ragweed challenge. a, Omalizumab group showed significant blunting of reduction in nasal volume after PD30 dose of ragweed (P < .001) at each visit compared with baseline. b, In the placebo group, there was no statistical significance between visits to baseline and to each other. Data are medians ± 95% CIs (∗∗∗P < .001). Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

4 FIG 2 Nasal challenge data on representative placebo-treated and omalizumab-treated subjects. The subject given placebo maintained a 30% reduction in nasal volume after ragweed nasal challenge compared with the subject given omalizumab, who had gradual blunted response to ragweed challenge, with onset at 7 to 14 days. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

5 FIG 3 Basophil FACS plots. a, Flow cytometric dot plot shows gating used to identify the basophil population (polygon). b, Representative basophil FcεRI staining before study (open histogram) and on day 42 of omalizumab (shaded histogram). Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

6 FIG 4 Effects of omalizumab on basophil FcεRI. Percentage of baseline MFI, median ± 95% CI. a, Significant reduction in FcεRI on basophils at all time points vs baseline (P < .001, Tukey-Kramer) in the omalizumab-treated group. b, No significant change in FcεRI on basophils in the placebo-treated group. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

7 FIG 4 Effects of omalizumab on basophil FcεRI. Percentage of baseline MFI, median ± 95% CI. a, Significant reduction in FcεRI on basophils at all time points vs baseline (P < .001, Tukey-Kramer) in the omalizumab-treated group. b, No significant change in FcεRI on basophils in the placebo-treated group. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

8 FIG 5 Correlation of basophil FcεRIα expression with serum IgE. For each subject, the fraction of IgE and FcεRI while receiving omalizumab relative to day 0 baseline was determined and plotted as described in the Methods section. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

Download ppt "Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils  Henry Lin, MD, Kevin M Boesel, MD, Daniel T Griffith, MD, Calman Prussin,"

Similar presentations

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy  Ravi S. Swamy, MD, Neha Reshamwala,

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy  Ravi S. Swamy, MD, Neha Reshamwala,
Serum granzymes and CD30 are increased in children's milk protein sensitive enteropathy and celiac disease  Merja T. Augustin, MD, Jorma Kokkonen, MD,

Serum granzymes and CD30 are increased in children's milk protein sensitive enteropathy and celiac disease  Merja T. Augustin, MD, Jorma Kokkonen, MD,
Serum granzymes and CD30 are increased in children's milk protein sensitive enteropathy and celiac disease  Merja T. Augustin, MD, Jorma Kokkonen, MD,

Serum granzymes and CD30 are increased in children's milk protein sensitive enteropathy and celiac disease  Merja T. Augustin, MD, Jorma Kokkonen, MD,
Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial  David M. Fleischer, MD, A. Wesley Burks,

Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial  David M. Fleischer, MD, A. Wesley Burks,
Alalia Berry, MD, William W. Busse, MD 

Alalia Berry, MD, William W. Busse, MD 
Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy  Michael Kulis, PhD, Katie.

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy  Michael Kulis, PhD, Katie.
Delayed clinical and ex vivo response to mammalian meat in patients with IgE to galactose-alpha-1,3-galactose  Scott P. Commins, MD, PhD, Hayley R. James,

Delayed clinical and ex vivo response to mammalian meat in patients with IgE to galactose-alpha-1,3-galactose  Scott P. Commins, MD, PhD, Hayley R. James,
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Anti-IgE treatment of eosinophil-associated gastrointestinal disorders

Anti-IgE treatment of eosinophil-associated gastrointestinal disorders
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Increased expression of nuclear factor of activated T cells 1 drives IL-9–mediated allergic asthma  Sonja Koch, PhD, Anna Graser, PhD, Hooman Mirzakhani,

Increased expression of nuclear factor of activated T cells 1 drives IL-9–mediated allergic asthma  Sonja Koch, PhD, Anna Graser, PhD, Hooman Mirzakhani,
Humanized mouse model of mast cell–mediated passive cutaneous anaphylaxis and passive systemic anaphylaxis  Paul J. Bryce, PhD, Rustom Falahati, PhD,

Humanized mouse model of mast cell–mediated passive cutaneous anaphylaxis and passive systemic anaphylaxis  Paul J. Bryce, PhD, Rustom Falahati, PhD,
The Editors' Choice Journal of Allergy and Clinical Immunology

The Editors' Choice Journal of Allergy and Clinical Immunology
Omalizumab treatment downregulates dendritic cell FcεRI expression

Omalizumab treatment downregulates dendritic cell FcεRI expression
Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy  Pamela A. Frischmeyer-Guerrerio, MD,

Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy  Pamela A. Frischmeyer-Guerrerio, MD,
The effect of omalizumab on nasal allergic inflammation

The effect of omalizumab on nasal allergic inflammation
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis  Friedrich Horak, MD, Kamal D.

Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis  Friedrich Horak, MD, Kamal D.
A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.

Similar presentations

Ads by Google